Polymorphism and ligand dependent changes in human glucagon-like peptide-1 receptor (GLP-1R) function: allosteric rescue of loss of function mutation

Cassandra Koole, Denise Wootten, John Simms, Celine Valant, Laurence J Miller, Arthur Christopoulos, Patrick M Sexton

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

The glucagon-like peptide-1 receptor (GLP-1R) is a key physiological regulator of insulin secretion and a major therapeutic target for the treatment of type II diabetes. However, regulation of GLP-1R function is complex with multiple endogenous peptides that interact with the receptor, including full-length (1-37) and truncated (7-37) forms of GLP-1 that can exist in an amidated form (GLP-1(1-36)NH₂ and GLP-1(7-36)NH₂) and the related peptide oxyntomodulin. In addition, the GLP-1R possesses exogenous agonists, including exendin-4, and the allosteric modulator, compound 2 (6,7-dichloro-2-methylsulfonyl-3-tert-butylaminoquinoxaline). The complexity of this ligand-receptor system is further increased by the presence of several single nucleotide polymorphisms (SNPs) that are distributed across the receptor. We have investigated 10 GLP-1R SNPs, which were characterized in three physiologically relevant signaling pathways (cAMP accumulation, extracellular signal-regulated kinase 1/2 phosphorylation, and intracellular Ca²⁺ mobilization); ligand binding and cell surface receptor expression were also determined. We demonstrate both ligand- and pathway-specific effects for multiple SNPs, with the most dramatic effect observed for the Met¹⁴⁹ receptor variant. At the Met¹⁴⁹ variant, there was selective loss of peptide-induced responses across all pathways examined, but preservation of response to the small molecule compound 2. In contrast, at the Cys³³³ variant, peptide responses were preserved but there was attenuated response to compound 2. Strikingly, the loss of peptide function at the Met¹⁴⁹ receptor variant could be allosterically rescued by compound 2, providing proof-of-principle evidence that allosteric drugs could be used to treat patients with this loss of function variant.

Original languageEnglish
Pages (from-to)486-497
Number of pages12
JournalMolecular Pharmacology
Volume80
Issue number3
DOIs
Publication statusPublished - Sep 2011

Fingerprint

Glucagon-Like Peptide 1
Ligands
Peptides
Mutation
Single Nucleotide Polymorphism
Oxyntomodulin
Mitogen-Activated Protein Kinase 3
Mitogen-Activated Protein Kinase 1
Cell Surface Receptors
Type 2 Diabetes Mellitus
Phosphorylation
Glucagon-Like Peptide-1 Receptor
Insulin
Pharmaceutical Preparations
Therapeutics

Keywords

  • Allosteric Regulation
  • Amino Acid Sequence
  • Glucagon-Like Peptide-1 Receptor
  • Humans
  • Ligands
  • Molecular Sequence Data
  • Mutagenesis
  • Phosphorylation
  • Polymorphism, Genetic
  • Radioligand Assay
  • Receptors, Glucagon
  • Journal Article
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

Cite this

Polymorphism and ligand dependent changes in human glucagon-like peptide-1 receptor (GLP-1R) function : allosteric rescue of loss of function mutation. / Koole, Cassandra; Wootten, Denise; Simms, John; Valant, Celine; Miller, Laurence J; Christopoulos, Arthur; Sexton, Patrick M.

In: Molecular Pharmacology, Vol. 80, No. 3, 09.2011, p. 486-497.

Research output: Contribution to journalArticle

Koole, Cassandra ; Wootten, Denise ; Simms, John ; Valant, Celine ; Miller, Laurence J ; Christopoulos, Arthur ; Sexton, Patrick M. / Polymorphism and ligand dependent changes in human glucagon-like peptide-1 receptor (GLP-1R) function : allosteric rescue of loss of function mutation. In: Molecular Pharmacology. 2011 ; Vol. 80, No. 3. pp. 486-497.
@article{3252e31ceaee40728ef660719ee37066,
title = "Polymorphism and ligand dependent changes in human glucagon-like peptide-1 receptor (GLP-1R) function: allosteric rescue of loss of function mutation",
abstract = "The glucagon-like peptide-1 receptor (GLP-1R) is a key physiological regulator of insulin secretion and a major therapeutic target for the treatment of type II diabetes. However, regulation of GLP-1R function is complex with multiple endogenous peptides that interact with the receptor, including full-length (1-37) and truncated (7-37) forms of GLP-1 that can exist in an amidated form (GLP-1(1-36)NH₂ and GLP-1(7-36)NH₂) and the related peptide oxyntomodulin. In addition, the GLP-1R possesses exogenous agonists, including exendin-4, and the allosteric modulator, compound 2 (6,7-dichloro-2-methylsulfonyl-3-tert-butylaminoquinoxaline). The complexity of this ligand-receptor system is further increased by the presence of several single nucleotide polymorphisms (SNPs) that are distributed across the receptor. We have investigated 10 GLP-1R SNPs, which were characterized in three physiologically relevant signaling pathways (cAMP accumulation, extracellular signal-regulated kinase 1/2 phosphorylation, and intracellular Ca²⁺ mobilization); ligand binding and cell surface receptor expression were also determined. We demonstrate both ligand- and pathway-specific effects for multiple SNPs, with the most dramatic effect observed for the Met¹⁴⁹ receptor variant. At the Met¹⁴⁹ variant, there was selective loss of peptide-induced responses across all pathways examined, but preservation of response to the small molecule compound 2. In contrast, at the Cys³³³ variant, peptide responses were preserved but there was attenuated response to compound 2. Strikingly, the loss of peptide function at the Met¹⁴⁹ receptor variant could be allosterically rescued by compound 2, providing proof-of-principle evidence that allosteric drugs could be used to treat patients with this loss of function variant.",
keywords = "Allosteric Regulation, Amino Acid Sequence, Glucagon-Like Peptide-1 Receptor, Humans, Ligands, Molecular Sequence Data, Mutagenesis, Phosphorylation, Polymorphism, Genetic, Radioligand Assay, Receptors, Glucagon, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't",
author = "Cassandra Koole and Denise Wootten and John Simms and Celine Valant and Miller, {Laurence J} and Arthur Christopoulos and Sexton, {Patrick M}",
year = "2011",
month = "9",
doi = "10.1124/mol.111.072884",
language = "English",
volume = "80",
pages = "486--497",
journal = "Molecular Pharmacology",
issn = "0026-895X",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "3",

}

TY - JOUR

T1 - Polymorphism and ligand dependent changes in human glucagon-like peptide-1 receptor (GLP-1R) function

T2 - allosteric rescue of loss of function mutation

AU - Koole, Cassandra

AU - Wootten, Denise

AU - Simms, John

AU - Valant, Celine

AU - Miller, Laurence J

AU - Christopoulos, Arthur

AU - Sexton, Patrick M

PY - 2011/9

Y1 - 2011/9

N2 - The glucagon-like peptide-1 receptor (GLP-1R) is a key physiological regulator of insulin secretion and a major therapeutic target for the treatment of type II diabetes. However, regulation of GLP-1R function is complex with multiple endogenous peptides that interact with the receptor, including full-length (1-37) and truncated (7-37) forms of GLP-1 that can exist in an amidated form (GLP-1(1-36)NH₂ and GLP-1(7-36)NH₂) and the related peptide oxyntomodulin. In addition, the GLP-1R possesses exogenous agonists, including exendin-4, and the allosteric modulator, compound 2 (6,7-dichloro-2-methylsulfonyl-3-tert-butylaminoquinoxaline). The complexity of this ligand-receptor system is further increased by the presence of several single nucleotide polymorphisms (SNPs) that are distributed across the receptor. We have investigated 10 GLP-1R SNPs, which were characterized in three physiologically relevant signaling pathways (cAMP accumulation, extracellular signal-regulated kinase 1/2 phosphorylation, and intracellular Ca²⁺ mobilization); ligand binding and cell surface receptor expression were also determined. We demonstrate both ligand- and pathway-specific effects for multiple SNPs, with the most dramatic effect observed for the Met¹⁴⁹ receptor variant. At the Met¹⁴⁹ variant, there was selective loss of peptide-induced responses across all pathways examined, but preservation of response to the small molecule compound 2. In contrast, at the Cys³³³ variant, peptide responses were preserved but there was attenuated response to compound 2. Strikingly, the loss of peptide function at the Met¹⁴⁹ receptor variant could be allosterically rescued by compound 2, providing proof-of-principle evidence that allosteric drugs could be used to treat patients with this loss of function variant.

AB - The glucagon-like peptide-1 receptor (GLP-1R) is a key physiological regulator of insulin secretion and a major therapeutic target for the treatment of type II diabetes. However, regulation of GLP-1R function is complex with multiple endogenous peptides that interact with the receptor, including full-length (1-37) and truncated (7-37) forms of GLP-1 that can exist in an amidated form (GLP-1(1-36)NH₂ and GLP-1(7-36)NH₂) and the related peptide oxyntomodulin. In addition, the GLP-1R possesses exogenous agonists, including exendin-4, and the allosteric modulator, compound 2 (6,7-dichloro-2-methylsulfonyl-3-tert-butylaminoquinoxaline). The complexity of this ligand-receptor system is further increased by the presence of several single nucleotide polymorphisms (SNPs) that are distributed across the receptor. We have investigated 10 GLP-1R SNPs, which were characterized in three physiologically relevant signaling pathways (cAMP accumulation, extracellular signal-regulated kinase 1/2 phosphorylation, and intracellular Ca²⁺ mobilization); ligand binding and cell surface receptor expression were also determined. We demonstrate both ligand- and pathway-specific effects for multiple SNPs, with the most dramatic effect observed for the Met¹⁴⁹ receptor variant. At the Met¹⁴⁹ variant, there was selective loss of peptide-induced responses across all pathways examined, but preservation of response to the small molecule compound 2. In contrast, at the Cys³³³ variant, peptide responses were preserved but there was attenuated response to compound 2. Strikingly, the loss of peptide function at the Met¹⁴⁹ receptor variant could be allosterically rescued by compound 2, providing proof-of-principle evidence that allosteric drugs could be used to treat patients with this loss of function variant.

KW - Allosteric Regulation

KW - Amino Acid Sequence

KW - Glucagon-Like Peptide-1 Receptor

KW - Humans

KW - Ligands

KW - Molecular Sequence Data

KW - Mutagenesis

KW - Phosphorylation

KW - Polymorphism, Genetic

KW - Radioligand Assay

KW - Receptors, Glucagon

KW - Journal Article

KW - Research Support, N.I.H., Extramural

KW - Research Support, Non-U.S. Gov't

U2 - 10.1124/mol.111.072884

DO - 10.1124/mol.111.072884

M3 - Article

VL - 80

SP - 486

EP - 497

JO - Molecular Pharmacology

JF - Molecular Pharmacology

SN - 0026-895X

IS - 3

ER -